Logo Image
|Articles|July 8, 2011

UBC Introduces Bracket, A Specialty Services Provider

United BioSource Corporation is pleased to introduce Bracket, a Specialty Services provider dedicated to helping pharmaceutical sponsors and contract research organizations (CROs) achieve greater certainty and accurate outcomes in their clinical trials. Bracket combines two existing UBC businesses: UBC's Clinical Technologies Group and Specialty Clinical Services business. The company's goal in operating these formerly distinct business units as one cohesive business is to leverage the integration of science, technology and operational excellence and expand our portfolio of specialty products so they can best help customers optimize their research and development activities.

Bracket will continue to offer its pre-approval specialty solutions, including e-Clinical Technologies such as IVRS, ePRO, and eLearning as well as comprehensive Endpoint Reliability Solutions that incorporate Rater Training, Endpoint Adjudication, Ratings Surveillance, and Computerized Cognitive Testing.

The alignment of this breadth of capability is designed to address the new paradigm in clinical development: one that demands tools and analytics to optimize decision-making and ultimately provide greater precision. Although operating under a new and distinct public brand, Bracket will remain a UBC company.

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more